← Back to patent-cliff list
Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals)
Tier C — Watch / tradeApomorphine Hydrochloride Injection (Britannia Pharmaceuticals)
Britannia Pharmaceuticals Ltd
Originator
2000
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：DRDs
Brand：Apomine, Li Ke Ji, Britaject, APO-go, Apokyn, ONAPGOTM, Apokinon, MOVAPO
Indications (approved)：Parkinson's disease
Regional status
US
-
EU
Approved
2000-01-01
China
Phase I
2023-07-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals)?
Approved indications include: Parkinson's disease.
When does the Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals) patent expire?
No public expiry year is available for Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27